Physician profile
Nancy J Human
NPI 1700950458
$938.33
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $511 · 2023: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $266.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.80 | 2021-2023 | Ozempic, Rybelsus |
| Amgen INC. | $100.37 | 2022 | |
| Lilly USA, LLC | $99.82 | 2021-2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $91.12 | 2022 | |
| Abbvie INC. | $78.39 | 2021-2023 | |
| Mylan Specialty L.P. | $65.30 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $57.26 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.09 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $32.49 | 2022-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Neurocrine Biosciences, INC. | $31.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.95 | 2023 | Eliquis |
| Lifescan, INC. | $22.65 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $22.14 | 2023 | Breztri |
| Sanofi Pasteur INC. | $17.05 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $14.54 | 2022 | |
| Biogen, INC. | $13.49 | 2023 | Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Human listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.